CHMP recommends EU approval of Roche’s fixed-duration Columvi for large B-cell lymphoma

Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma

CiRA, Kyoto University and Astellas Phase 2 research agreement signed for iPS Cells

CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells

LyGenesis and Imagine Pharma to jointly develop cell therapies for Patients with Type 1 diabetes

Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes

AnaBios acquires Cell Systems to expand human cell portfolio for drug discovery

Immutep announces expansion of triple combination therapy in first-line non-small cell lung cancer

Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations

Thermo Fisher Scientific opens cell therapy facility at University of California

The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.

Agilent announces cell analysis workflow automation for immuno-oncology, virology, and vaccine development markets

New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator

Asahi Kasei completes construction of microcrystalline cellulose plant

With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC

Thermo Fisher Scientific to introduce fully automated cell line automation platform

Thermo Fisher and Celltrio bring first-in-kind automation platform to address critical scale-up challenges in biotherapeutics RoboCell cell line automation platform

FDA approves Keytruda as adjuvant treatment for non-small cell lung cancer

Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US